The role of biological agents in the management of large vessel vasculitis (LVV): A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Osman, Mohammed ^a   Pagnoux, Christian ^b   Dryden, Donna M ^a   Storie, Dale ^a   Yacyshyn, Elaine ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; PLACEBO; PREDNISONE; RITUXIMAB; TOCILIZUMAB; BIOLOGICAL FACTOR;

ADRENAL INSUFFICIENCY; ALLERGIC RASH; ALLERGY; AORTA ARCH SYNDROME; ARTICLE; BREAST CANCER; CASE CONTROL STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GIANT CELL ARTERITIS; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LARGE VESSEL VASCULITIS; LEUKOPENIA; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCREAS CANCER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK BENEFIT ANALYSIS; SERUM SICKNESS; SIDE EFFECT; SYSTEMATIC REVIEW; VASCULITIS; WEIGHT REDUCTION; TAKAYASU ARTERITIS;

BIOLOGICAL FACTORS; GIANT CELL ARTERITIS; HUMANS; TAKAYASU ARTERITIS;

EID: 84919476951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115026     Document Type: Article

References (48)

1. Jennette J, Falk R, Bacon P, Basu N, Cid M, et al. (2012) 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum.
2. Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, et al. (2012) Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 71: 1329-1334.
3. Weyand CM, Ma-Krupa W, Goronzy JJ (2004) Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 3: 46-53.
4. Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372: 234-245.
5. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33: 1129-1134.
6. Unizony S, Stone JH, Stone JR (2013) New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 25: 3-9.
7. Li C, Dasgupta B (2000) Corticosteroids in polymyalgia rheumatica-a review of different treatment schedules. Clin Exp Rheumatol 18: S56-57.
8. Kotter I, Henes JC, Wagner AD, Loock J, Gross WL (2012) Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 30: S114-129.
9. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, et al. (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56: 2789-2797.
10. Pipitone N, Olivieri I, Salvarani C, Italian Society of R (2012) Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 30: S139-161.
11. Schafer VS, Zwerina J (2012) Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 24: 31-37.
12. Osman M, Pagnoux C, Storie D, Dryden D, Homik J, et al. (2012) PROSPERO: International Prospective Register of Systematic Reviews. Centre for Reviews and Dissemination review protocol: CRD42012003138.
13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
14. Seida JC, LeBlanc C, Schouten JR, Mousavi SS, Hartling L, et al. (2010) Systematic review: nonoperative and operative treatments for rotator cuff tears. Ann Intern Med 153: 246-255.
15. Borenstein M HL, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. Chichester, UK: John Wiley & Sons.
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
17. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, et al. (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64: 1720-1729.
18. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, et al. (2013) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis.
19. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, et al. (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Medical Weekly 141: w13156.
20. Sciascia S, Rossi D, Roccatello D (2011) Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. Journal of Rheumatology 38: 2080-2081.
21. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, et al. (2012) Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford, England) 51: 151-156.
22. Osman M, Aaron S, Noga M, Yacyshyn E (2011) Takayasu's arteritis progression on anti-TNF biologics: a case series. Clinical Rheumatology 30: 703-706.
23. Nunes G, Neves FS, Melo FM, de Castro GRW, Zimmermann AF, et al. (2010) Takayasu arteritis: anti- TNF therapy in a Brazilian setting. Revista Brasileira de Reumatologia 50: 291-298.
24. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Annals of the Rheumatic Diseases 67: 1567-1569.
25. Mekinian A, Neel A, Sibilia J, Cohen P, Connault J, et al. (2012) Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology 51: 882-886.
26. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, et al. (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the Rheumatic Diseases 67: 625-630.
27. Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN (2007) Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 26: 984-987.
28. Kaneko U, Kishi T, Kikuchi M, Hara R, Shinoki T, et al. (2010) Infliximab therapy for three adolescent patients with refractory Takayasu's arteritis. [Japanese]. Japanese Journal of Clinical Immunology 33: 317-323.
29. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, et al. (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71: 75-79.
30. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, et al. (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. [Summary for patients in Ann Intern Med. 2007 May 1; 146(9):I12; PMID: 17470826]. Annals of Internal Medicine 146: 621-630.
31. Galarza C, Valencia D, Tobon GJ, Zurita L, Mantilla RD, et al. (2008) Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clinical Reviews in Allergy & Immunology 34: 124-128.
32. Filocamo G, Buoncompagni A, Viola S, Loy A, Malattia C, et al. (2008) Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. Journal of Pediatrics 153: 432-434.
33. Della Rossa A, Tavoni A, Merlini G, Baldini C, Sebastiani M, et al. (2005) Two Takayasu arteritis patients successfully treated with infliximab: A potential disease-modifying agent? Rheumatology (Oxford) 44: 1074-1075.
34. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, et al. (2012) Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity Reviews 11: 678-684.
35. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44: 2933-2935.
36. Cañas C, Izquierdo JH, Bonilla F (2012) EFFICACY OF ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY (TOCILIZUMAB) IN COLOMBIAN PATIENTS WITH TAKAYASU'S ARTERITIS. Ann Rheum Dis 71: 681.
37. Buonuomo PS, Bracaglia C, Campana A, Insalaco A, Pardeo M, et al. (2011) Infliximab therapy in pediatric Takayasu's arteritis: report of two cases. Rheumatol Int 31: 93-95.
38. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, et al. (2011) Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Annals of the Rheumatic Diseases 70: 1874-1875.
39. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G (2003) Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Annals of the Rheumatic Diseases 62: 1116.
40. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, et al. (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care and Research 64: 1079-1083.
41. Cantini F, Niccoli L, Nannini C, Porciello G, Storri L, et al. (2003) Long-term follow up of patients with refractory giant cell arteritis (GCA) treated with infliximab (abstract) - no body relapsed. Annals of the Rheumatic Diseases 62: 207-207.
42. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis & Rheumatism 50: 2296-2304.
43. Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, et al. (2013) Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013: 912562.
44. Ishihara T, Haraguchi G, Tezuka D, Kamiishi T, Inagaki H, et al. (2013) Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ J 77: 477-483.
45. Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, et al. (2011) Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 155: 425-433.
46. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E (2013) Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 40: 2047-2051.
47. Xenitidis T, Horger M, Zeh G, Kanz L, Henes JC (2013) Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 52: 1729-1731.
48. Tezuka D, Haraguchi G, Ishihara T, Ohigashi H, Inagaki H, et al. (2012) Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 5: 422-429.